142 related articles for article (PubMed ID: 10637237)
1. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy.
Presant CA; Wolf W; Waluch V; Wiseman CL; Weitz I; Shani J
J Clin Oncol; 2000 Jan; 18(2):255-61. PubMed ID: 10637237
[TBL] [Abstract][Full Text] [Related]
2. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
[TBL] [Abstract][Full Text] [Related]
3. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
[TBL] [Abstract][Full Text] [Related]
4. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
[TBL] [Abstract][Full Text] [Related]
5. The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study.
Findlay MP; Leach MO; Cunningham D; Collins DJ; Payne GS; Glaholm J; Mansi JL; McCready VR
Ann Oncol; 1993 Aug; 4(7):597-602. PubMed ID: 8363990
[TBL] [Abstract][Full Text] [Related]
6. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma.
Dimitrakopoulou-Strauss A; Strauss LG; Schlag P; Hohenberger P; Irngartinger G; Oberdorfer F; Doll J; van Kaick G
J Nucl Med; 1998 Mar; 39(3):465-73. PubMed ID: 9529293
[TBL] [Abstract][Full Text] [Related]
7. Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study.
Presant CA; Jacobson J; Wolf W; Waluch V; Weitz IC; Macdonald JS;
Invest New Drugs; 2002 Nov; 20(4):369-76. PubMed ID: 12448653
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.
Kissel J; Brix G; Bellemann ME; Strauss LG; Dimitrakopoulou-Strauss A; Port R; Haberkorn U; Lorenz WJ
Cancer Res; 1997 Aug; 57(16):3415-23. PubMed ID: 9270007
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy.
Katzir I; Shani J; Wolf W; Chatterjee-Parti S; Berman E
Cancer Invest; 2000; 18(1):20-7. PubMed ID: 10701363
[TBL] [Abstract][Full Text] [Related]
11. Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
Grem JL; Chu E; Boarman D; Balis FM; Murphy RF; McAtee N; Allegra CJ
Semin Oncol; 1992 Apr; 19(2 Suppl 3):36-44. PubMed ID: 1557656
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
Kerr DJ; Ledermann JA; McArdle CS; Buckels J; Neoptolemos J; Seymour M; Doughty J; Budden J; Taylor I
J Clin Oncol; 1995 Dec; 13(12):2968-72. PubMed ID: 8523062
[TBL] [Abstract][Full Text] [Related]
13. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
van Laarhoven HW; Klomp DW; Rijpkema M; Kamm YL; Wagener DJ; Barentsz JO; Punt CJ; Heerschap A
NMR Biomed; 2007 Apr; 20(2):128-40. PubMed ID: 17006886
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo.
Tausch-Treml R; Baumgart F; Ziessow D; Köpf-Maier P
Cancer Chemother Pharmacol; 1996; 37(3):259-65. PubMed ID: 8529287
[TBL] [Abstract][Full Text] [Related]
15. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.
Moehler M; Dimitrakopoulou-Strauss A; Gutzler F; Raeth U; Strauss LG; Stremmel W
Cancer; 1998 Jul; 83(2):245-53. PubMed ID: 9669806
[TBL] [Abstract][Full Text] [Related]
16. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
[TBL] [Abstract][Full Text] [Related]
17. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
18. Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Martens-Lobenhoffer J; Fuhlroth J; Ridwelski K
Int J Clin Pharmacol Ther; 2000 Jan; 38(1):41-4. PubMed ID: 10667836
[TBL] [Abstract][Full Text] [Related]
19. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.
Gupta N; Saleem A; Kötz B; Osman S; Aboagye EO; Phillips R; Vernon C; Wasan H; Jones T; Hoskin PJ; Price PM
Clin Cancer Res; 2006 May; 12(10):3115-23. PubMed ID: 16707610
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
